Mifepristone Mail Distribution Remains Available Amid FDA Review Deadline Looming

A federal judge has allowed abortion pill mifepristone to continue being distributed by mail nationwide for now, but warned that the Biden-era policy could soon face major legal changes as a Food and Drug Administration review deadline is looming. The FDA had requested a 6-month extension for its review of the medication, which remains available by mail despite ongoing litigation. This decision comes amidst ongoing debates over reproductive rights and access to abortion pills in the US.